TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06307743

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
Study: NCT06226545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: High dose of LASN01 will be administered intravenously.
Study: NCT06470815

Intervention type: PROCEDURE
Intervention: Transcarotid Artery Revascularization (TCAR)
Description: Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
Study: NCT06279650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: The HYlaDo intervention comprises 8 90-minute sessions. Session 1 offers psycho-education on pain and medical hypnosis. Sessions 2 to 7 offer brief introductions followed by hypnosis induction, during which the CBT elements (exposure and cognitive restructuring) to be worked on during the session are introduced. The sessions are aimed at managing: 2- anxiety and mood; 3- pain dramatization; 4- and 5- pain perception; 6- kinesiophobia; 7- future projection and resource mobilization. Session 8 provides feedback and recommendations for independent practice. Each hypnosis follows the same pattern: induction, deepening, CBT-based hypnotic work, post-hypnotic suggestions and return to wakefulness, explanations of the exercise and recommendations for independent practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education and cognitive Bahavioral therapy (CBT)
Description: The psychoeducation-CBT intervention for pain and anxiety/depression consists of 8 90-minute sessions. It has already been implemented in HMR's pain clinic, and controls both the effects of time and repetition of measures, as well as non-specific factors including expectations associated with receiving active treatment, therapeutic relationship, frequency of encounters, and participation in a manualized intervention. It is designed to inform participants about pain, its costs, neurophysiology, nature and impact. It includes general information on pain, as well as information tailored to the participants' particular type of pain. The sessions are interactive, with the therapist stimulating discussion of the educational content and its relevance to the participants' lives.
Study: NCT06134934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring 1
Description: This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring 2
Description: This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
Study: NCT06026111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Description: Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
Study: NCT05843786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma
Description: Daily subcutaneous administration of Interferon gamma during 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during 5 days
Study: NCT06362733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth
Description: This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and parent-mediated intervention with the child.
Study: NCT05085990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
Study: NCT04914403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06-05
Description: Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
Study: NCT05773092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral S-1 + Oral Osimertinib
Description: S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
Study: NCT06364553

Intervention type: DEVICE
Group type: OTHER
Intervention: Esophageal self-expandable metal stent
Description: The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
Study: NCT05222646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Will receive single dose of 10mg of Metoclopramide intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Will receive single dose of 10mg of Metoclopramide intramuscularly
Study: NCT05543044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Description: Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
Study: NCT06302660

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of urine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of stool.

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related Quality of life questionnaires
Description: Participants will attend an outpatient clinic and complete validated healthy-related quality-of-life questionnaires.
Study: NCT05104229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care VTE prophylaxis
Study: NCT06388954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)
Description: Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve.~Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side eﬀect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Trancutaneous auricular Vagus Nerve Stimulation
Description: Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation. The active electrodes will be attached to the left cymba conchae. The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
Study: NCT06582212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mymovesmatter mobile application
Description: Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
Study: NCT05291286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
Study: NCT06588660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vevoctadekin
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04981730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Description: The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
Study: NCT06421051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation
Study: NCT06417775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ubrogepant
Description: Oral Tablets
Study: NCT05005403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-514
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-514
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-514
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-514
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study: NCT06369220

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cobas® liat CT/NG/MG nucleic acid test
Description: The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC): Clinician's Standard Practice
Description: Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
Study: NCT06788990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficerafusp alfa
Description: Investigational

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficerafusp alfa
Description: Investigational
Study: NCT06304220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerazet
Description: Comparation of the utilization of two distinct progestogens for pituitary suppression
Study: NCT06788990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficerafusp alfa
Description: Investigational

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent
Study: NCT05685966

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06788990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent
Study: NCT05152589

Intervention type: DIAGNOSTIC_TEST
Intervention: hearing test
Description: Auditory Brainstem Response (ABR) Test

Intervention type: DIAGNOSTIC_TEST
Intervention: hearing test
Description: Auditory Brainstem Response (ABR) Test

Intervention type: DIAGNOSTIC_TEST
Intervention: hearing test
Description: Auditory Brainstem Response (ABR) Test
Study: NCT06788990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study: NCT06484322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies Empowering Activities in Everyday life (SEE 2.0)
Description: SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
Study: NCT05923463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: precision-enhanced feedback email messages
Description: Providers receive customized messages prioritizing metrics in an optimal formatting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard feedback email messages
Description: Providers receive metrics in a common format.
Study: NCT05322525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream
Description: Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day
Study: NCT04851249

Intervention type: PROCEDURE
Intervention: Hallux Valgus - chevron osteotomy, lapidus procedure
Description: The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
Study: NCT04580953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiaCareTM RR2
Description: Treatment with CardiaCareTM RR2
Study: NCT06787144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: Orally once daily
Study: NCT06784492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Intervention-1
Description: Participants will receive a text or email each day with instructions about a healthy intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Intervention-2
Description: Participants will receive a text or email each day with instructions about a healthy intervention.
Study: NCT06789692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tobacco smoking substitution products
Description: Offer of preference-based smoking substitution menu, consisting of e-cigarettes or nicotine pouches or nicotine patches in addition to standard of care. This menu will be offered by the treating physician during the routine cohort visit and the participant can choose one product to test as an alternative to tobacco smoking. The products will be handed out directly after the consultation and are provided free of charge for 6 months.
Study: NCT05166057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized online telerehabilitation exercise program
Description: Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videobased telerehabilitation exercise program
Description: A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital based outpatient exercise program
Description: Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
Study: NCT06097468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NisinZ® P
Description: NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NisinZ® P
Description: NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (non-interventional, standard of care)
Description: Surgical removal of tumor as part of standard of care treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (non-interventional, standard of care)
Description: Surgical removal of tumor as part of standard of care treatment
Study: NCT06791486

Intervention type: OTHER
Intervention: AI-assisted predictive model
Description: This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.

Intervention type: OTHER
Intervention: AI-assisted predictive model
Description: This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.
Study: NCT04573920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Film-coated tablet